First-in-human uPAR PET: Imaging of Cancer Aggressiveness

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

First-in-human uPAR PET : Imaging of Cancer Aggressiveness. / Persson, Morten; Skovgaard, Dorthe; Brandt-Larsen, Malene; Christensen, Camilla; Madsen, Jacob; Nielsen, Carsten H; Røndbjerg, Tine Thurison; Klausen, Thomas Levin; Holm, Søren; Loft, Annika; Berthelsen, Anne Kiil; Ploug, Michael; Pappot, Helle; Brasso, Klaus; Kroman, Niels; Højgaard, Liselotte; Kjaer, Andreas.

In: Theranostics, Vol. 5, No. 12, 2015, p. 1303-16.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Persson, M, Skovgaard, D, Brandt-Larsen, M, Christensen, C, Madsen, J, Nielsen, CH, Røndbjerg, TT, Klausen, TL, Holm, S, Loft, A, Berthelsen, AK, Ploug, M, Pappot, H, Brasso, K, Kroman, N, Højgaard, L & Kjaer, A 2015, 'First-in-human uPAR PET: Imaging of Cancer Aggressiveness', Theranostics, vol. 5, no. 12, pp. 1303-16. https://doi.org/10.7150/thno.12956

APA

Persson, M., Skovgaard, D., Brandt-Larsen, M., Christensen, C., Madsen, J., Nielsen, C. H., ... Kjaer, A. (2015). First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics, 5(12), 1303-16. https://doi.org/10.7150/thno.12956

Vancouver

Persson M, Skovgaard D, Brandt-Larsen M, Christensen C, Madsen J, Nielsen CH et al. First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics. 2015;5(12):1303-16. https://doi.org/10.7150/thno.12956

Author

Persson, Morten ; Skovgaard, Dorthe ; Brandt-Larsen, Malene ; Christensen, Camilla ; Madsen, Jacob ; Nielsen, Carsten H ; Røndbjerg, Tine Thurison ; Klausen, Thomas Levin ; Holm, Søren ; Loft, Annika ; Berthelsen, Anne Kiil ; Ploug, Michael ; Pappot, Helle ; Brasso, Klaus ; Kroman, Niels ; Højgaard, Liselotte ; Kjaer, Andreas. / First-in-human uPAR PET : Imaging of Cancer Aggressiveness. In: Theranostics. 2015 ; Vol. 5, No. 12. pp. 1303-16.

Bibtex

@article{2a3ee04e72bf4e3991042834e0aece00,
title = "First-in-human uPAR PET: Imaging of Cancer Aggressiveness",
abstract = "A first-in-human clinical trial with Positron Emission Tomography (PET) imaging of the urokinase-type plasminogen activator receptor (uPAR) in patients with breast, prostate and bladder cancer, is described. uPAR is expressed in many types of human cancers and the expression is predictive of invasion, metastasis and indicates poor prognosis. uPAR PET imaging therefore holds promise to be a new and innovative method for improved cancer diagnosis, staging and individual risk stratification. The uPAR specific peptide AE105 was conjugated to the macrocyclic chelator DOTA and labeled with (64)Cu for targeted molecular imaging with PET. The safety, pharmacokinetic, biodistribution profile and radiation dosimetry after a single intravenous dose of (64)Cu-DOTA-AE105 were assessed by serial PET and computed tomography (CT) in 4 prostate, 3 breast and 3 bladder cancer patients. Safety assessment with laboratory blood screening tests was performed before and after PET ligand injection. In a subgroup of the patients, the in vivo stability of our targeted PET ligand was determined in collected blood and urine. No adverse or clinically detectable side effects in any of the 10 patients were found. The ligand exhibited good in vivo stability and fast clearance from plasma and tissue compartments by renal excretion. In addition, high uptake in both primary tumor lesions and lymph node metastases was seen and paralleled high uPAR expression in excised tumor tissue. Overall, this first-in-human study therefore provides promising evidence for safe use of (64)Cu-DOTA-AE105 for uPAR PET imaging in cancer patients.",
author = "Morten Persson and Dorthe Skovgaard and Malene Brandt-Larsen and Camilla Christensen and Jacob Madsen and Nielsen, {Carsten H} and R{\o}ndbjerg, {Tine Thurison} and Klausen, {Thomas Levin} and S{\o}ren Holm and Annika Loft and Berthelsen, {Anne Kiil} and Michael Ploug and Helle Pappot and Klaus Brasso and Niels Kroman and Liselotte H{\o}jgaard and Andreas Kjaer",
year = "2015",
doi = "10.7150/thno.12956",
language = "English",
volume = "5",
pages = "1303--16",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "12",

}

RIS

TY - JOUR

T1 - First-in-human uPAR PET

T2 - Imaging of Cancer Aggressiveness

AU - Persson, Morten

AU - Skovgaard, Dorthe

AU - Brandt-Larsen, Malene

AU - Christensen, Camilla

AU - Madsen, Jacob

AU - Nielsen, Carsten H

AU - Røndbjerg, Tine Thurison

AU - Klausen, Thomas Levin

AU - Holm, Søren

AU - Loft, Annika

AU - Berthelsen, Anne Kiil

AU - Ploug, Michael

AU - Pappot, Helle

AU - Brasso, Klaus

AU - Kroman, Niels

AU - Højgaard, Liselotte

AU - Kjaer, Andreas

PY - 2015

Y1 - 2015

N2 - A first-in-human clinical trial with Positron Emission Tomography (PET) imaging of the urokinase-type plasminogen activator receptor (uPAR) in patients with breast, prostate and bladder cancer, is described. uPAR is expressed in many types of human cancers and the expression is predictive of invasion, metastasis and indicates poor prognosis. uPAR PET imaging therefore holds promise to be a new and innovative method for improved cancer diagnosis, staging and individual risk stratification. The uPAR specific peptide AE105 was conjugated to the macrocyclic chelator DOTA and labeled with (64)Cu for targeted molecular imaging with PET. The safety, pharmacokinetic, biodistribution profile and radiation dosimetry after a single intravenous dose of (64)Cu-DOTA-AE105 were assessed by serial PET and computed tomography (CT) in 4 prostate, 3 breast and 3 bladder cancer patients. Safety assessment with laboratory blood screening tests was performed before and after PET ligand injection. In a subgroup of the patients, the in vivo stability of our targeted PET ligand was determined in collected blood and urine. No adverse or clinically detectable side effects in any of the 10 patients were found. The ligand exhibited good in vivo stability and fast clearance from plasma and tissue compartments by renal excretion. In addition, high uptake in both primary tumor lesions and lymph node metastases was seen and paralleled high uPAR expression in excised tumor tissue. Overall, this first-in-human study therefore provides promising evidence for safe use of (64)Cu-DOTA-AE105 for uPAR PET imaging in cancer patients.

AB - A first-in-human clinical trial with Positron Emission Tomography (PET) imaging of the urokinase-type plasminogen activator receptor (uPAR) in patients with breast, prostate and bladder cancer, is described. uPAR is expressed in many types of human cancers and the expression is predictive of invasion, metastasis and indicates poor prognosis. uPAR PET imaging therefore holds promise to be a new and innovative method for improved cancer diagnosis, staging and individual risk stratification. The uPAR specific peptide AE105 was conjugated to the macrocyclic chelator DOTA and labeled with (64)Cu for targeted molecular imaging with PET. The safety, pharmacokinetic, biodistribution profile and radiation dosimetry after a single intravenous dose of (64)Cu-DOTA-AE105 were assessed by serial PET and computed tomography (CT) in 4 prostate, 3 breast and 3 bladder cancer patients. Safety assessment with laboratory blood screening tests was performed before and after PET ligand injection. In a subgroup of the patients, the in vivo stability of our targeted PET ligand was determined in collected blood and urine. No adverse or clinically detectable side effects in any of the 10 patients were found. The ligand exhibited good in vivo stability and fast clearance from plasma and tissue compartments by renal excretion. In addition, high uptake in both primary tumor lesions and lymph node metastases was seen and paralleled high uPAR expression in excised tumor tissue. Overall, this first-in-human study therefore provides promising evidence for safe use of (64)Cu-DOTA-AE105 for uPAR PET imaging in cancer patients.

U2 - 10.7150/thno.12956

DO - 10.7150/thno.12956

M3 - Journal article

C2 - 26516369

VL - 5

SP - 1303

EP - 1316

JO - Theranostics

JF - Theranostics

SN - 1838-7640

IS - 12

ER -

ID: 147663017